FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036123102> ?p ?o ?g. }

• W3036123102 endingPage "6" @default.
• W3036123102 startingPage "1" @default.
• W3036123102 abstract "To evaluate the efficacy and safety of apatinib, an oral antiangiogenic drug, in patients with recurrent or refractory cervical cancer as salvage treatment, we retrospectively analyzed the medical records of recurrent or refractory cervical cancer patients admitted to the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Hunan Cancer Hospital, from October 1, 2016, to December 31, 2017. Patients who progressed within 6 months after the last treatment were given apatinib orally at a dose of 250 mg daily until disease progression or unacceptable toxicity. Twenty-nine patients were enrolled in our retrospective study. Up to February 1, 2019, the median follow-up time was 18 months. The median progression-free survival was 128 days (95% confidence interval (CI): 20–540 days), and the median overall survival was 9 months (95% CI: 4–23 months). The longest period of apatinib administration was 540 days. No complete response was observed, 5 (17.2%) patients achieved partial response, and 11 (37.9%) achieved stable disease. The objective response rate and disease control rate were 17.2% and 55.1%, respectively. The most common adverse events were hypertension (G1, 65.5%, 19/29), mucositis (G1, 55.2%, 16/29), hand-foot syndrome (G1-2, 44.8%, 13/29), and proteinuria (G1-2, 20.7%, 6/29). Grade 3 proteinuria occurred in only one patient (3.4%, 1/29). Apatinib single-agent use might be an effective and tolerable choice as salvage therapy for patients with recurrent or refractory cervical cancer." @default.
• W3036123102 created "2020-06-25" @default.
• W3036123102 creator A5015105154 @default.
• W3036123102 creator A5031810848 @default.
• W3036123102 creator A5034686784 @default.
• W3036123102 creator A5037677450 @default.
• W3036123102 creator A5039289212 @default.
• W3036123102 creator A5061667981 @default.
• W3036123102 creator A5076637933 @default.
• W3036123102 creator A5083967189 @default.
• W3036123102 creator A5086053207 @default.
• W3036123102 date "2020-06-22" @default.
• W3036123102 modified "2023-09-25" @default.
• W3036123102 title "An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study" @default.
• W3036123102 cites W1816099873 @default.
• W3036123102 cites W2006618501 @default.
• W3036123102 cites W2011814551 @default.
• W3036123102 cites W2019607817 @default.
• W3036123102 cites W2078397784 @default.
• W3036123102 cites W2100756525 @default.
• W3036123102 cites W2126768246 @default.
• W3036123102 cites W2138881782 @default.
• W3036123102 cites W2145092426 @default.
• W3036123102 cites W2272984102 @default.
• W3036123102 cites W2275009125 @default.
• W3036123102 cites W2276228008 @default.
• W3036123102 cites W2338002224 @default.
• W3036123102 cites W2472375270 @default.
• W3036123102 cites W2474810458 @default.
• W3036123102 cites W2806333996 @default.
• W3036123102 cites W2883906054 @default.
• W3036123102 cites W2895516423 @default.
• W3036123102 cites W2961501196 @default.
• W3036123102 cites W2975280344 @default.
• W3036123102 cites W2988663711 @default.
• W3036123102 cites W2995828290 @default.
• W3036123102 doi "https://doi.org/10.1155/2020/3852373" @default.
• W3036123102 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7327550" @default.
• W3036123102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32655637" @default.
• W3036123102 hasPublicationYear "2020" @default.
• W3036123102 type Work @default.
• W3036123102 sameAs 3036123102 @default.
• W3036123102 citedByCount "9" @default.
• W3036123102 countsByYear W30361231022020 @default.
• W3036123102 countsByYear W30361231022021 @default.
• W3036123102 countsByYear W30361231022022 @default.
• W3036123102 countsByYear W30361231022023 @default.
• W3036123102 crossrefType "journal-article" @default.
• W3036123102 hasAuthorship W3036123102A5015105154 @default.
• W3036123102 hasAuthorship W3036123102A5031810848 @default.
• W3036123102 hasAuthorship W3036123102A5034686784 @default.
• W3036123102 hasAuthorship W3036123102A5037677450 @default.
• W3036123102 hasAuthorship W3036123102A5039289212 @default.
• W3036123102 hasAuthorship W3036123102A5061667981 @default.
• W3036123102 hasAuthorship W3036123102A5076637933 @default.
• W3036123102 hasAuthorship W3036123102A5083967189 @default.
• W3036123102 hasAuthorship W3036123102A5086053207 @default.
• W3036123102 hasBestOaLocation W30361231021 @default.
• W3036123102 hasConcept C121332964 @default.
• W3036123102 hasConcept C121608353 @default.
• W3036123102 hasConcept C126322002 @default.
• W3036123102 hasConcept C141071460 @default.
• W3036123102 hasConcept C142424586 @default.
• W3036123102 hasConcept C167135981 @default.
• W3036123102 hasConcept C197934379 @default.
• W3036123102 hasConcept C2778220009 @default.
• W3036123102 hasConcept C2778496288 @default.
• W3036123102 hasConcept C2778822529 @default.
• W3036123102 hasConcept C2779134260 @default.
• W3036123102 hasConcept C2779561371 @default.
• W3036123102 hasConcept C2780091579 @default.
• W3036123102 hasConcept C2780668389 @default.
• W3036123102 hasConcept C29730261 @default.
• W3036123102 hasConcept C71924100 @default.
• W3036123102 hasConcept C87355193 @default.
• W3036123102 hasConcept C90924648 @default.
• W3036123102 hasConceptScore W3036123102C121332964 @default.
• W3036123102 hasConceptScore W3036123102C121608353 @default.
• W3036123102 hasConceptScore W3036123102C126322002 @default.
• W3036123102 hasConceptScore W3036123102C141071460 @default.
• W3036123102 hasConceptScore W3036123102C142424586 @default.
• W3036123102 hasConceptScore W3036123102C167135981 @default.
• W3036123102 hasConceptScore W3036123102C197934379 @default.
• W3036123102 hasConceptScore W3036123102C2778220009 @default.
• W3036123102 hasConceptScore W3036123102C2778496288 @default.
• W3036123102 hasConceptScore W3036123102C2778822529 @default.
• W3036123102 hasConceptScore W3036123102C2779134260 @default.
• W3036123102 hasConceptScore W3036123102C2779561371 @default.
• W3036123102 hasConceptScore W3036123102C2780091579 @default.
• W3036123102 hasConceptScore W3036123102C2780668389 @default.
• W3036123102 hasConceptScore W3036123102C29730261 @default.
• W3036123102 hasConceptScore W3036123102C71924100 @default.
• W3036123102 hasConceptScore W3036123102C87355193 @default.
• W3036123102 hasConceptScore W3036123102C90924648 @default.
• W3036123102 hasFunder F4320323137 @default.
• W3036123102 hasLocation W30361231021 @default.
• W3036123102 hasLocation W30361231022 @default.
• W3036123102 hasLocation W30361231023 @default.

• next